The RBI has signaled confidence in India's price stability by projecting Q4 FY26 inflation at 3.2%, despite firmed-up growth expectations following the recent India-US trade agreement. The central bank maintained the repo rate at 5.25% with a neutral stance.
Team Sahi
Market snapshot: In the final bi-monthly monetary policy address of the 2025-26 fiscal year, RBI Governor Sanjay Malhotra projected a benign inflation trajectory, with Consumer Price Index (CPI) inflation expected to settle at 3.2% in Q4 FY26. This comes as the Monetary Policy Committee (MPC) unanimously decided to keep the repo rate unchanged at 5.25%, following a significant easing cycle in 2025 that saw cumulative cuts of 125 basis points.
Summary: The RBI has signaled confidence in India's price stability by projecting Q4 FY26 inflation at 3.2%, despite firmed-up growth expectations following the recent India-US trade agreement. The central bank maintained the repo rate at 5.25% with a neutral stance.
The RBI's projection of 3.2% is strategically positioned within the 2-6% tolerance band but reflects a cautious uptick from the record lows of late 2025. By maintaining the repo rate at 5.25%, the RBI is balancing the 'Goldilocks' phase of high growth (7.4% GDP projection) and controlled inflation. Investors should view this as a commitment to long-term stability, providing a fertile ground for equity markets despite intensified global headwinds.
The projected 3.2% inflation print underscores the success of the RBI's preceding rate-cut cycle and the cooling of food prices. As India transitions to a modernized statistical framework, the central bank appears well-equipped to sustain a steady growth-inflation balance.
High Performance Trading with SAHI.
Related
Recent
Fed's 2026 Outlook: Economic Resilience Meets Persistent Inflationary Pressures
Geopolitical Brinkmanship: Trump-Iran Tensions and the Indian Market Outlook
Zydus Lifesciences Disrupts Respiratory Care with Indiaās First Drug-Free Device 'Pepair' at ā¹990
Infosys Pivots to 'AI-First' Era: New Framework Targets $300 Billion Market Opportunity
Zydus Lifesciences Disrupts Respiratory Care with Indiaās First Affordable Drug-Free Device āPepairTMā at ā¹990